The increase in the number of opioid products with abuse-deterrent properties, both approved and in development, has FDA's external experts concerned about the marketing and public health implications of such claims.
During the June 7 review of Teva Pharmaceutical Industries Ltd.'s Vantrela (hydrocodone extended-release), advisory committee members looked beyond the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?